A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.

Phase 2

Pfizer

Tofacitinib